Received Sep 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
reported administering twinrix at double the recommended dose as therapeutic vaccination in a CHB patient; reported administering twinrix at double the recommended dose as therapeutic vaccination in a CHB patient; This non-serious case was reported by a physician via sales rep and described the occurrence of overdose in a patient who received HAB (Twinrix) for prophylaxis. Concurrent medical conditions included chronic hepatitis b. On an unknown date, the patient received Twinrix. On an unknown date, an unknown time after receiving Twinrix, the patient experienced overdose (Verbatim: reported administering twinrix at double the recommended dose as therapeutic vaccination in a CHB patient) and drug use for unapproved indication (Verbatim: reported administering twinrix at double the recommended dose as therapeutic vaccination in a CHB patient). The outcome of the overdose and drug use for unapproved indication were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.
Chronic hepatitis B